Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenu archivé le 2024-06-16

Manipulating tumour suppression: a key to improve cancer treatment

Objectif

The prevention of human cancer development depends on the integrity of the cellular defence mechanisms that respond to stress.A key player in this defence is the p53 tumour suppressor, which eliminates cancer cells by inhibiting their growth.These p53 functions often affect the efficacy of anti-cancer therapies.While p53 is often mutated in human cancers, it remain normal in about 50% of cases, notably in breast carcinoma. the non-mutated p53 could be activated to suppress tumour progression.Deregulation of p53 modulators, such as Mdm2 or p73, can hampered p53 tumour suppression activities by acting upstream and/or downstream of p53.It is crucial to understand how p53 modulators contribute to human malignancies.Based on this information, we propose to develop rational theraupetic approaches to manipulate p53 modulators,thereby wakening the sleeping tumour suppressive activities of p53, allowing it to eliminate cancer cells.A carefully structured consortium will interactively build a technology platform to comparatively identify,characterize and evaluate the regulatory roles of p53-modulators and define the mechanisms of their action.Large-scale gene functional analyses will be conducted to identify relevant signalling pathways that impair or mediate tumour suppression by p53.These analyses will include p53 activators and inhibitors, p53 homologues p73/p63,and dissection of p53 targets genes mediating apoptosis and growth arrest.Our links with highly profiled clinical partners and our access to large, well-characterized and clinically documented sample collections will enable the evaluation of diagnostic expression profiles, and their potential prognosis value in cancer.Particular emphasis will be directed towards translating basic knowledge of functional oncogenomics into cancer diagnoses, treatment and identification of new molecular targets for drug discovery and contributing to leadership in European health technology.

Champ scientifique

Mots‑clés

Programme(s)

Thème(s)

Appel à propositions

FP6-2002-LIFESCIHEALTH
Voir d’autres projets de cet appel

Régime de financement

IP - Integrated Project

Coordinateur

REGINA ELENA CANCER INSTITUTE
Contribution de l’UE
Aucune donnée
Adresse
Via Elio Chianesi, 53
ROME
Italie

Voir sur la carte
Coût total
Aucune donnée

Participants (25)

Partager cette page

Télécharger

Dernière mise à jour: 5 Avril 2023

Mon livret

Permalink: https://cordis.europa.eu/project/id/503576/fr

European Union, 2024